Muscular Dystrophy Gene Panel (NGS) in the UAE

Executive Summary & Core Metrics

Diagnostic Accuracy: 99.9% diagnostic sensitivity via ISO-certified next-generation sequencing processing.
Premium Logistics: VIP Mobile Phlebotomy with hospital-grade home sample collection and temperature-controlled cold-chain transport available daily from 8 AM to 11 PM.
Clinical Guidance: Post-test telephonic consultation with a consultant medical geneticist for comprehensive result interpretation.
Insurance Verification: Direct insurance coverage verification and pre-authorisation support via WhatsApp +971 54 548 8731.

Test Overview & Methodology

The Muscular Dystrophy Gene Panel (NGS) is a comprehensive next-generation sequencing test that screens for pathogenic variants in genes associated with all major muscular dystrophy subtypes, including Duchenne (DMD), Becker (DMD), Limb-Girdle (LGMD), Emery-Dreifuss, Facioscapulohumeral, Congenital Muscular Dystrophy, and Myotonic Dystrophy. The test enables precise molecular diagnosis, carrier status identification, prognostic stratification, and tailored clinical management planning. Results must be correlated with clinical examination, family history, and creatine kinase levels for definitive diagnostic confirmation.

Feature	Our Test (Muscular Dystrophy NGS Panel)	Closest Alternative (Traditional Single-Gene / MLPA)
Precision & Coverage	99.9% diagnostic sensitivity; full sequencing of all muscular dystrophy-associated genes (DMD, LGMD spectrum, congenital, myotonic, and Emery-Dreifuss loci)	Limited to specific deletion/duplication hotspots; misses point mutations, small insertions/deletions, and deep intronic variants
Methodology	Next Generation Sequencing (NGS) with optional Sanger confirmation of clinically significant variants	Multiplex Ligation-dependent Probe Amplification (MLPA) or single-exon Sanger sequencing for isolated regions
Turnaround Time	4 to 5 weeks	2 to 3 weeks but incomplete coverage and lower reliability for unusual variants
Clinical Utility	Definitive molecular diagnosis, carrier screening, prognosis guidance, and eligibility assessment for emerging gene therapies	Presumptive screening only; frequent need for additional reflex testing with higher cumulative cost

Physician Insight & Safety Protocols

"Genetic testing for muscular dystrophy requires careful pre-test counselling and thorough post-test interpretation. This panel provides comprehensive molecular insights across all major dystrophy genes, but I strongly emphasise that results must be correlated with clinical examination, family pedigree analysis, and serum creatine kinase levels. Patients should discuss all findings with their referring physician and a certified genetic counsellor before making any medical decisions regarding treatment, surveillance, or family planning."

— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403

Important Advisory: Medication Continuation

Do not discontinue, alter, or adjust any prescribed medication, including corticosteroids, cardiac therapies, or respiratory support regimens, without direct consultation with your treating physician. Genetic test results may inform future treatment decisions but should never prompt immediate medication changes without clinical correlation.

Safety Exclusion Criteria & Emergency Red Flags

Exclusion Criteria: Patients with severe coagulopathy or on full-dose anticoagulation therapy must obtain physician clearance before blood collection. A brief pre-collection haematology consultation is advised. Individuals with acute febrile illness or active infection should defer sampling until clinically stable.
Emergency Red Flags: If you experience sudden onset of difficulty breathing, chest pain, palpitations, acute muscle cramping with dark urine, or loss of consciousness, seek emergency medical care immediately. These symptoms may indicate rhabdomyolysis, cardiac arrhythmia, or a rapidly progressing neuromuscular crisis requiring urgent intervention.

Patient FAQ & Clinical Guidance

1. What is the Muscular Dystrophy Gene Panel and who should consider it?

A: This advanced next-generation sequencing panel detects mutations in genes that cause all major forms of muscular dystrophy, including Duchenne, Becker, Limb-Girdle, Facioscapulohumeral, Congenital, and Myotonic Dystrophy. It is recommended for individuals with progressive muscle weakness, elevated creatine kinase levels, abnormal electromyography findings, or a positive family history of neuromuscular disease. The test also serves as a carrier screening tool for at-risk family members.

2. How is the sample collected and what is the turnaround time?

A: A standard venous blood sample (3 to 5 mL in an EDTA tube) or a DNA FTA card is collected by our trained phlebotomists. We offer VIP Mobile Phlebotomy with hospital-grade cold-chain transport to our ISO-certified laboratory. All samples are processed under strict temperature monitoring protocols. Results are available within 4 to 5 weeks from sample receipt, and a telephonic consultation with a consultant medical geneticist is provided upon result delivery.

3. Does insurance cover this genetic test and how can I verify my coverage?

A: Most UAE health insurance plans cover genetic testing for muscular dystrophy when ordered by a licensed physician with a documented clinical indication. Our insurance team handles direct billing verification and can communicate with your insurer before your appointment. To verify your specific coverage, please send a photo of your insurance card via WhatsApp to +971 54 548 8731, and our team will confirm eligibility and any applicable copayment or deductible within one business day.

4. What preparation is required before the blood draw?

A: No special dietary preparation or fasting is required for this genetic test. However, you must bring a valid Emirates ID, your health insurance card, and the physician referral / prescription for the test. If you are on anticoagulant therapy, please inform our phlebotomist during scheduling. It is also recommended to stay well hydrated before the blood draw to facilitate vein access.

UAE Regulatory & Data Privacy Adherence

This diagnostic service strictly adheres to Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) governing the collection, processing, and storage of genetic data, and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields for electronic health information security. All clinical procedures, patient consent protocols, and safety standards comply with Federal Decree-Law No. 4 of 2016 on Medical Liability. The laboratory operates under DHA Facility License Number 1143 and maintains ISO 9001:2015 quality management certification. Genetic data is encrypted and stored on UAE-based servers with restricted access, and results are disclosed only to the ordering physician and the patient with explicit written consent.

Clinical & Logistical Metadata

Test Name	Muscular Dystrophy Gene Panel (NGS)
Price (AED)	2,400
Turnaround Time	4 to 5 weeks
Sample Type / Matrix	Standard Venous Whole Blood (EDTA) or DNA FTA Card
Methodology Used	Next Generation Sequencing (NGS) with optional Sanger confirmation
ICD-10-CM Code	G71.0
LOINC Code	98134-7
DHA Facility License & Laboratory Address	DHA Facility License Number: 1143 \| Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE \| DNA Labs UAE